CRHR2 Antibody

What is CRHR2 and what cellular functions does it mediate?

CRHR2 is a G-protein coupled receptor for corticotropin-releasing hormone (CRH), urocortin (UCN), UCN2, and UCN3. It plays significant roles in mediating stress responses in both central and peripheral tissues. Ligand binding to CRHR2 triggers conformational changes that activate signaling via G proteins and downstream effectors, particularly adenylate cyclase, which increases intracellular cAMP levels . CRHR2 is expressed in diverse tissues including the brain, heart, gastrointestinal tract, and skeletal muscle, where it coordinates endocrine, autonomic, and behavioral responses to stress .

What are the key considerations when selecting a CRHR2 antibody for research?

When selecting a CRHR2 antibody, researchers should consider:

• Target epitope location: Antibodies targeting different regions (N-terminal, extracellular, or central regions) may have different accessibility depending on experimental conditions .

• Species reactivity: Confirm cross-reactivity with your experimental model. Some antibodies show high homology across species (human, mouse, rat, etc.) .

• Application compatibility: Verify the antibody has been validated for your intended application (WB, IHC, IF/ICC, ELISA, FCM) .

• Clonality: Polyclonal antibodies may provide broader epitope recognition but potentially less specificity compared to monoclonal antibodies .

• Validation data: Review available performance data including predicted reactivity percentages and positive control recommendations .

How can I confirm the specificity of my CRHR2 antibody?

To verify antibody specificity:

• Positive controls: Use tissues known to express CRHR2 (e.g., brain, heart, lung tissues) .

• Negative controls: Use primary antibody omission or non-immune IgG of the same species.

• Peptide competition: Pre-incubate the antibody with the immunizing peptide to block specific binding.

• Predicted band size verification: Confirm detection at the expected molecular weight (~48 kDa) .

• Multiple antibody approach: Use antibodies targeting different epitopes to corroborate findings .

What are the optimal fixation and sample preparation methods for CRHR2 immunohistochemistry?

For optimal CRHR2 detection in tissue sections:

• Fixation: Formalin-fixed, paraffin-embedded (FFPE) tissues work well for CRHR2 detection using established antibodies .

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) or Tris-EDTA (pH 9.0) is recommended to unmask epitopes.

• Blocking: Use 3-5% normal serum from the species of the secondary antibody for 1 hour at room temperature.

• Antibody dilution: Begin with manufacturer-recommended dilutions (typically 1:50-1:200 for IHC-P) and optimize as needed .

• Signal amplification: Consider using polymer-based detection systems for enhanced sensitivity in tissues with low CRHR2 expression.

• Counterstaining: Light hematoxylin counterstaining helps visualize tissue architecture without obscuring specific staining .

How should Western blot protocols be optimized for CRHR2 detection?

For successful Western blot detection of CRHR2:

• Protein extraction: Use membrane protein extraction methods since CRHR2 is a transmembrane receptor.

• Sample preparation: Avoid excessive heating of samples which may cause receptor aggregation.

• Gel percentage: Use 10-12% SDS-PAGE gels for optimal resolution around 48 kDa (predicted CRHR2 molecular weight) .

• Transfer conditions: Semi-dry or wet transfer at lower voltages (e.g., 30V overnight) may improve transfer of membrane proteins.

• Blocking: 5% non-fat dry milk in TBST is typically effective; for phospho-specific detection, use 5% BSA.

• Antibody dilution: Most CRHR2 antibodies work optimally at 1:500-1:1000 dilution for Western blot .

• Membrane washing: Multiple TBST washes (5 × 5 minutes) between antibody incubations to reduce background.

How can I simultaneously detect CRHR1 and CRHR2 to study their differential expression and function?

To investigate differential CRHR1 and CRHR2 expression:

• Sequential IHC/IF: Perform sequential staining with antibodies raised in different host species, using spectrally distinct fluorophores.

• Multiplex Western blotting: Strip and reprobe membranes, or use fluorescent secondary antibodies with different emission spectra.

• Species considerations: Choose antibodies with minimal cross-reactivity between CRHR1 and CRHR2 epitopes.

• Controls: Include single-stained samples to confirm antibody specificity and absence of signal bleed-through.

• Analysis approach: Quantify relative receptor levels using imaging software with co-localization analysis capabilities .

Research indicates CRHR1 and CRHR2 often have distinct distribution patterns and opposing functional roles, with CRHR1 associated with anxiety and pro-inflammatory responses, while CRHR2 mediates anxiolytic and anti-inflammatory effects .

What are the key considerations when studying CRHR2 function in serotonergic systems?

When investigating CRHR2 in serotonergic pathways:

• Receptor antagonist studies: Use selective CRHR2 antagonists (e.g., antisauvagine-30) for mechanistic studies of CRHR2-specific functions .

• Regional considerations: Focus on functionally distinct serotonergic regions (dorsal raphe nucleus subdivisions, median raphe nucleus) .

• Temporal dynamics: Consider diurnal variations in expression; TPH2 protein peaks approximately 8 hours after mRNA expression peaks .

• Stress paradigms: Incorporate acute stress models to study CRHR2 involvement in stress-induced changes in 5-HT synthesis .

• Microdissection approach: For higher resolution analysis, use precise microdissection techniques to isolate specific nuclei .

• Correlative measurements: Combine measures of receptor expression with functional readouts (e.g., 5-HTP accumulation as an index of TPH2 activity) .

How can I accurately interpret CRHR2 immunostaining in cancer tissues and correlate with clinical outcomes?

For cancer tissue CRHR2 analysis:

• Scoring methodology:

  • Establish clear positive/negative thresholds (e.g., >10% positive carcinoma cells is frequently used as cutoff for cytoplasmic immunostaining) .

  • Consider scoring based on both percentage of positive cells and staining intensity.

• Statistical approaches:

  • Use appropriate statistical tests (e.g., Student's t-test, χ² test) to evaluate associations between CRHR2 status and clinicopathological factors.

  • Generate survival curves using Kaplan-Meier method and analyze with Cox proportional hazard model.

  • Consider CRHR2 status alongside other prognostic markers in multivariate analysis .

• Interpretation context:

  • CRHR2 status has been marginally associated with better clinical outcomes in some cancers, contrasting with CRHR1 which has been linked to worse prognosis .

  • Consider analyzing both receptors and their ligands for more comprehensive understanding.

How can I address non-specific binding when using CRHR2 antibodies in immunohistochemistry?

To minimize non-specific binding:

• Optimization strategies:

  • Antibody titration: Test serial dilutions to determine optimal concentration balancing specific signal and background.

  • Blocking optimization: Extend blocking time (2-3 hours) or increase blocking reagent concentration (5-10%).

  • Wash protocol enhancement: Increase wash duration or number of wash steps.

  • Secondary antibody selection: Choose highly cross-adsorbed secondary antibodies.

• Technical troubleshooting:

  • Endogenous peroxidase quenching: Use 3% H₂O₂ in methanol (10-15 minutes) before antibody incubation.

  • Biotin blocking: If using avidin-biotin systems, block endogenous biotin using commercial kits.

  • Antibody diluent: Add 0.1-0.3% Triton X-100 to reduce non-specific hydrophobic interactions.

  • Antigen retrieval modification: Test different pH buffers or retrieval times .

What approaches can address inconsistent Western blot results when detecting CRHR2?

For more consistent Western blot results:

• Sample preparation refinements:

  • Protein extraction method: Use specialized membrane protein extraction buffers containing mild detergents.

  • Protease inhibitors: Always include fresh protease inhibitor cocktail.

  • Sample handling: Avoid repeated freeze-thaw cycles of protein samples.

  • Loading controls: Include appropriate controls for membrane proteins (Na⁺/K⁺ ATPase, pan-cadherin).

• Protocol modifications:

  • Blocking agent testing: Compare milk vs. BSA vs. commercial blocking reagents.

  • Antibody incubation: Extend primary antibody incubation time (overnight at 4°C).

  • Detection system: Try enhanced chemiluminescence plus (ECL+) or fluorescent secondary antibodies.

  • Multiple antibody approach: Validate findings with antibodies targeting different epitopes .

How can CRHR2 antibodies be utilized to investigate the receptor's role in cardiovascular function and pathophysiology?

For cardiovascular CRHR2 research:

• Tissue-specific applications:

  • Use immunohistochemistry to map CRHR2 distribution across cardiac tissues and vasculature.

  • Combine with functional studies using selective CRHR2 agonists/antagonists.

  • Employ co-immunoprecipitation to identify cardiac-specific binding partners.

• Pathophysiological investigations:

  • Compare CRHR2 expression in normal vs. diseased cardiac tissue.

  • Examine receptor regulation during cardiac stress responses.

  • Correlate CRHR2 levels with markers of inflammation and fibrosis.

• Receptor signaling pathway analysis:

  • Use phospho-specific antibodies to track downstream signaling activation.

  • Investigate how CRHR2 signaling intersects with other cardiac stress response pathways.

  • Examine differential affinities of urocortins vs. CRH in cardiac tissue .

What methodological approaches can help investigate CRHR2 involvement in the gut-brain axis?

For gut-brain axis CRHR2 studies:

• Dual-tissue analysis approaches:

  • Simultaneous CRHR2 detection in gut and CNS tissues from the same experimental subjects.

  • Correlation of receptor levels with stress biomarkers and gut permeability measures.

  • Receptor visualization in enteric nervous system using whole-mount preparations.

• Functional correlation techniques:

  • Combine receptor localization with electrophysiological recordings.

  • Use cell-type specific markers to identify CRHR2-expressing cell populations.

  • Employ optogenetic or chemogenetic approaches targeting CRHR2-positive neurons.

• Translational research considerations:

  • Compare receptor distribution across species to validate animal models.

  • Consider receptor polymorphisms when designing human studies.

  • Investigate how nutritional status affects receptor expression and function .